Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China
- PMID: 27149911
- PMCID: PMC4858717
- DOI: 10.1038/srep25330
Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China
Abstract
New diagnostic methods have provided a promising solution for rapid and reliable detection of drug-resistant TB strains. The aim of this study was to evaluate the performance of the MeltPro TB assay in identifying multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) patients from sputum samples. The MeltPro TB assay was evaluated using sputum samples from 2057 smear-positive TB patients. Phenotypic Mycobacterial Growth Indicator Tube (MGIT) 960 drug susceptibility testing served as a reference standard. The sensitivity of the MeltPro TB assay was 94.2% for detecting resistance to rifampicin and 84.9% for detecting resistance to isoniazid. For second-line drugs, the assay showed a sensitivity of 83.3% for ofloxacin resistance, 75.0% for amikacin resistance, and 63.5% for kanamycin resistance. However, there was a significant difference for detecting kanamycin resistance between the two pilot sites in sensitivity, which was 53.2% in Guangdong and 81.5% in Shandong (P = 0.015). Overall, the MeltPro TB assay demonstrated good performance for the detection of MDR- and XDR-TB, with a sensitivity of 86.7% and 71.4%, respectively. The MeltPro TB assay is an excellent alternative for the detection of MDR- and XDR-TB cases in China, with high accuracy, short testing turn-around time, and low unit price compared with other tests.
Figures
References
-
- Zumla A. et al. Drug-resistant tuberculosis–current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis. 205, Suppl 2, S228–240 (2012). - PubMed
-
- World Health Oragnization. Global tuberculosis report 2014. World Health Organization, Geneva, Switherland. WHO/HTM/TB/2014.08 (2014).
-
- Wright A. et al. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373, 1861–1873 (2009). - PubMed
-
- Van Rie A. & Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet 368, 1554–1556 (2006). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
